

5-1 2

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT	Attorney Docket: PF454 Applicant: Gentz et al	Application No: 09/006,352 Group: 1634
---	--	--

[illegible][illegible][illegible]

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

#15

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)				Complete If Known			
				Application Number		09/006,352	
				Filing Date		January 13, 1998	
				First Named Inventor		Gentz et al.	
				Group Art Unit		1632	
				Examiner Name		Bekerleg, A.	
				Attorney Docket Number		PF454	
Sheet	1		of	2			

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Code ² Number (if known)	Kind	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
EPA	AG	5,632,994		REED ET AL.	05-27-97	
EPA	AH	5,874,546		NAGATA ET AL.	02-23-99	
EPA	AI	5,652,210		BARR ET AL.	07-29-97	
EPA	AJ	5,663,070		BARR ET AL.	09-02-97	
EPA	AK	5,620,889		LYNCH ET AL.	04-15-97	
EPA	AL	5,830,469		LYNCH ET AL.	11-03-98	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Office ³ Code ⁵ Number ⁴ (if known)	Kind	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
EPA	AM	EP 0 861 850		SMITHKLINE BEECHAM CORPORATION	09-02-98		
EPA	AN	WO99/14330		GENENTECH, INC.	03-25-99		
EPA	AO	WO00/01817		SCHERING CORPORATION	01-13-00		
EPA	AP	WO99/07738		REGENERON PHARMACEUTICALS, INC.	02-18-99		
EPA	AQ	WO99/04001		ZYMOGENETICS, INC.	01-28-99		
EPA	AR	WO99/26977		BIOGEN, INC.	11-24-98		
EPA	AS	WO99/46376		BASF AKTIENGESSELLSCHAFT	09-16-99	abstract	
EPA	AT	WO98/56892		HUMAN GENOME SCIENCES, INC.	12-17-98		
EPA	AU	WO99/33980		CHIRON CORPORATION	07-08-99		
EPA	AV	WO99/11791		UNIVERSITY OF WASHINGTON	03-11-99		
EPA	AW	WO99/31128		INCYTE PHARMACEUTICALS, INC.	06-24-99		
EPA	AX	WO99/50413		ELI LILLY AND COMPANY	10-07-99		

File Copy

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)		Application Number	09/006,352
		Filing Date	January 13, 1998
		First Named Inventor	Gentz et al.
		Group Art Unit	1632
		Examiner Name	Beckerleg, A.
Sheet	2	of	2
		Attorney Docket Number	PF454

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
EJA	AY	PITTL et al., <i>Nature</i> , 396:699-703 (12-17-98)	
EJA	AZ	RABINOWICH et al., "Lymphocyte Apoptosis Induced by Fas Ligand-expressing Ovarian Carcinoma Cells," <i>J. Clin. Invest.</i> 101(11):2579-2588 (06-98)	
EJA	BA	WALKER et al., "Tumor expression of Fas ligand (CD95L) and the consequences," <i>Current Opinion in Immunology</i> 10:564-572 (1998)	
EJA	BB	GRATAS, et al., "Up-Regulation of Fas (APO-1/CD95) Ligand and Down-Regulation of Fas Expression in Human Esophageal Cancer," <i>Cancer Research</i> 58:2057-2062 (05-15-98)	
Examiner		Date Considered	
Eileen B. O'Hara		5/23/02	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

#21

Please type a plus sign (+) inside this box → ☐PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/006,352	
			Filing Date	Jan 13, 1998	
			First Named Inventor	Gentz, et al.	
			Group Art Unit	1646	
			Examiner Name	O'Hara, Eileen	
Sheet	1	of	1	Attorney Docket Number	PF454

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
EA	BC	09/912,293		ROSEN ET AL.	NOT PUBLISHED	pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 29783 and 63238
EA	BD	6,297,367		TRIBOULEY	10-02-2001	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
EA	BE	ADAMS et al., Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. <i>Nature</i> 377 (6547 Suppl):3-174 (1995)	
EA	BF	ADAMS et al., Genbank Accession Number AA325843 (04-20-1997)	
EA	BG	HILLIER et al., Genbank Accession Number AA025672 (02-01-1997)	
EA	BH	Zhang et al., Modulation of T-cell responses to alloantigens by TR6/DcR3. <i>J. Clin Invest.</i> 107:1459-1468.	

Examiner Signature	Eileen B. O'Hara	Date Considered	5/23/02
--------------------	------------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

File Copy